Homology Medicines Declares Distribution to Common Stockholders
March 18, 2024 16:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of...
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
January 03, 2024 16:08 ET
|
Homology Medicines, Inc.
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology...
Q32 Bio and Homology Medicines Announce Merger Agreement
November 16, 2023 07:05 ET
|
Homology Medicines, Inc.
--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic...
Homology Medicines Reports Third Quarter 2023 Financial Results
November 14, 2023 16:33 ET
|
Homology Medicines, Inc.
- Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc....
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023 16:05 ET
|
Homology Medicines, Inc.
- Reported Encouraging Initial Data from First Cohort of Phase 1 Trial Evaluating Gene Editing Candidate HMI-103 in Adults with PKU - - Evaluating Strategic Options for the Company and Pipeline of...
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
July 27, 2023 16:05 ET
|
Homology Medicines, Inc.
Announced Today Encouraging Initial Clinical Data from First Dose Level of pheEDIT Trial Evaluating HMI-103 BEDFORD, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq:...
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
July 27, 2023 16:01 ET
|
Homology Medicines, Inc.
Participant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold (<360 μmol/L)*; At 31 Weeks Post-Dose,...
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
May 16, 2023 08:00 ET
|
Homology Medicines, Inc.
- New Preclinical Data Demonstrated Ability to Re-Dose with AAVHSCs Across Viral Clades, Potentially Expanding Possibilities of Genetic Medicine Programs in the Future - - Presented Methods to...
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023 16:05 ET
|
Homology Medicines, Inc.
- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 - - First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and...
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting
May 03, 2023 07:30 ET
|
Homology Medicines, Inc.
- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency - BEDFORD, Mass., May 03, 2023 (GLOBE...